Akers Biosciences (AKER +11.8%) perks up on double normal volume in reaction to its announcement that it, and collaboration partner Premas Biotech, have successfully expressed three coronavirus antigens (spike, envelope and membrane) that they selected for their vaccine candidate, the second milestone in their partnership.

Two days ago, it announced that they had cloned the three antigens which was the first milestone.

https://seekingalpha.com/news/3559328-akers-bio-up-12-on-progress-in-coronavirus-partnership